CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

About this update from Cns Pharmaceuticals, Inc.

Segment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel Goldlust Access the segment here HOUSTON, TX / ACCESSWIRE / October 10, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment . The segment can be accessed here . As part of the event, John Climaco , Chief Executive Officer, Dr. Sandra Silberman , Chief Medical Officer, Dr. Don Picker , Chief Scientific Officer , and Dr. Samuel Goldlust , a leading Neuro-Oncologist and Key Opinion Leader who currently serves as the Medical Director of Neuro-Oncology at Saint Luke's Health System and previously an investigator in the Company's global potentially pivotal study of Berubicin, provided a corporate overview, discussed the unmet need in glioblastoma multiforme (GBM) and discussed the CNS opportunity. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. For more information, please visit www.CNSPharma.com , and connect with the Company on X , Facebook , and LinkedIn . CONTACTS: Investor Relations Contact JTC Team, LLC Jenene Thomas 908.824.0775 [email protected] SOURCE: CNS Pharmaceuticals, Inc. View the original press release on accesswire.com

View stock analysis, news, and events for Cns Pharmaceuticals, Inc.